HotSpot Therapeutics Presents MALT1 CBM Signalosome Glue Preclinical Data at 36th EORTC-NCI-AACR Symposium

BOSTON, Oct. 23, 2024 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology firm, has announced the presentation of preclinical data for its promising therapy targeting the MALT1 protein. The findings will be showcased at the 36th EORTC-NCI-AACR Symposium and emphasize the therapy's potential in treating NF-kB-driven solid tumors.

MALT1 is integral to the CBM protein complex, playing a significant role in regulating NF-kB signaling within cells, particularly B and T cells. The dysfunction of MALT1 is associated with various hematological cancers and solid tumors. HotSpot Therapeutics has utilized its innovative Smart Allostery™ platform to create a small molecule signalosome glue that selectively inhibits MALT1's scaffolding function, crucial for NF-kB pathway activation, while preserving its protease activity.

Geraldine Harriman, Ph.D., Chief Scientific Officer at HotSpot Therapeutics, emphasized the unique capabilities of their Smart Allostery™ platform. She noted, "Our platform has facilitated the creation of a MALT1 signalosome glue that specifically targets the scaffolding function of MALT1, achieving a distinct activity profile enabling profound inhibition of the NF-kB pathway. Given the well-established role of NF-kB signaling in oncogenesis, these preclinical findings support HST-1021's potential as a precision oncology treatment for NF-kB-driven solid tumors."

The preclinical data for HST-1021, presented during the symposium, highlighted several promising aspects:

1. HST-1021 exhibited strong inhibition of CBM signalosome activity, distinguishing it from MALT1 protease inhibitors.
2. In an NF-kB-driven nasopharyngeal carcinoma patient-derived xenograft model, HST-1021 showed dose-dependent anti-tumor effects, showcasing its potential effectiveness in treating NF-kB-driven solid tumors.

HotSpot Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to pioneering a new class of allosteric drugs aimed at natural hotspots on proteins. These specific pockets on proteins control cellular functions and offer substantial potential for novel drug discovery. Utilizing its proprietary Smart Allostery™ platform, HotSpot combines computational approaches and AI-driven data analysis to identify and target these hotspots. This approach facilitates the rapid development of potent and selective small molecules with unique pharmacology.

By leveraging their innovative platform, HotSpot Therapeutics is building a diverse pipeline of new allosteric therapies targeting cancer and autoimmune diseases. The company is committed to advancing the frontier of drug discovery and development, aiming to bring novel treatments to patients in need.

HotSpot Therapeutics' recent preclinical data presentation at the EORTC-NCI-AACR Symposium underscores the company's progress in developing groundbreaking therapies for complex diseases. The promising results for HST-1021 illustrate the potential impact of their Smart Allostery™ platform and signal significant advancements in precision oncology.

HotSpot Therapeutics continues to explore the vast possibilities of allosteric drug development, aiming to offer new hope for patients with challenging conditions. The company's innovative approach and dedication to scientific excellence position it as a key player in the biotechnology landscape.